


Ensuring patients have access to innovative cancer therapies - what can policymakers do?

Immuno-oncology: a policy action framework
19th November 2014
Brussels, European Parliament

Cedrik M. Britten



Immunotherapy targets the immune system !

Immuno-Oncology

Immunomodulatory Antibodies



Immune response

Tumor response

Patient survival

Adoptive Cell Transfer





Immune-receptor transfer



Vaccines



Other immune manipulations



Classical Therapies in Oncology
(surgery, irradiation, chemotherapy, antibodies binding to tumor surface antigens)

A development framework for I.O.


Oncoimmunology 1:3, 1–6; May/June 2012; © 2012 Landes Bioscience

REVIEW

The immuno-oncology framework

Enabling a new era of cancer therapy

Axel Hoos^{1*} and Cedrik M. Britten^{2,3}



What is the solution ?

1 Better Understanding for what is unique about Immuno-Oncology



...this will enhance clinical development and appropriate clinical use of novel treatments

What is the solution ?


Measuring what matters



...this includes search for validated intermediate endpoints that are predictive of long-term survival

What is the solution ?

Flexible regulatory framework **3**




...this will allow to balance the need for patient safety with the wish to make the best innovation accessible for patients

Case 1 - „The non-responder phenomenon“

Novel treatment options in Oncology

- In the last decade progress in science has led to powerful new drugs that have become available for the treatment of cancer
- The next slide will list the „TOP“ 15 drugs in oncology ranked by their sales volume

Case 1 - „The non-responder phenomenon“




Drug Discovery Today

Clinical benefit for the 15 most successful therapies in oncology observed in ~35%

Case 1 - „The non-responder phenomenon“

Immuno-Oncology: checkpoint inhibitory antibodies



One fraction of patients benefits from the novel treatment but a considerable fraction of patients does not respond to the treatment

Case 1 - „The non-responder phenomenon“


What is the issue ?

Risks for patients that do **not respond** to a given treatment?

- Risk for treatment-related side effects
- Risk for delay of the next (efficacious) line of treatment
- Costs associated with the treatment

What is the solution ?


- 4 Invest more in research to understand how immuno-oncology works in patients



...this will allow to select the right patient for a given treatment !

What is the solution ?

5 Comprehensive pathways and funding for innovative cancer therapies



...this will ensure equitable access to innovative therapies

Thank you !

